NumFin

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Simbolis: 2196.HK

HKSE

13.28

HKD

Rinkos kaina šiandien

  • 15.5749

    P/E santykis

  • 7.2266

    PEG koeficientas

  • 63.71B

    MRK kapitalizacija

  • 0.04%

    DIV pajamingumas

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196-HK) Finansinės ataskaitos

Download
MetinisKetvirtinis
LinijinisLoginis
Diagramoje matote numatytuosius skaičius dinamikoje Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK). Įmonės pajamos rodo NaN M vidurkį, kuris yra NaN % gowth. Vidutinis viso laikotarpio bendrasis pelnas yra NaN M, kuris yra NaN %. Vidutinis bendrojo pelno rodiklis yra NaN %. Įmonės praėjusių metų veiklos grynojo pelno augimas yra NaN %, kuris lygus NaN % % vidutiniškai per visą bendrovės istoriją.,

MetinisKetvirtinis
10Y20Y30Y40Y

Balansas

Pasinerdami į Shanghai Fosun Pharmaceutical (Group) Co., Ltd. fiskalinę trajektoriją, stebime vidutinį turto augimą. Įdomu tai, kad šis rodiklis yra , atspindintis tiek aukščiausias, tiek žemiausias įmonės rodiklius. Palyginus per ketvirtį, šis skaičius pakoreguojamas iki . Žvilgtelėjus į praėjusius metus, matyti, kad bendras turto pokytis yra NaN. Akcininkų vertė, kurią parodo bendras akcininkų nuosavas kapitalas, vertinama pagal NaN ataskaitine valiuta. Šio aspekto pokytis per metus yra NaN%.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

balance-sheet.row.cash-and-short-term-investments

015582.117169.814549.2
11931.9
9989.9
9162.6
7468.2
6044.5
4062.4
3729.5
3111.6
5197.4
3125.9
3562.3
1308.5
1005.7
1079.6
991.3
752.9
688.1
1242.6
629.4
373.1
343.4
170
329.8
25.3
6.6
7.2

balance-sheet.row.short-term-investments

01888.5928.54241.1
1970.1
456.7
616.1
219.3
48.5
33.8
33.8
44.2
224.8
231.3
218.8
11.7
0.1
5.8
2.1
0
5.2
0.2
285.3
0.9
0
0
0
0
0
0

balance-sheet.row.net-receivables

09967.910797.89517.7
7256.7
5873.4
5255.7
4522.5
2976.9
2518.7
3318.7
2256.4
1906.4
1797.3
1426.6
925.2
940.2
732.1
811
673.6
618.3
536.6
406.4
545.2
37.5
58.4
31.4
9.1
5.1
26.3

balance-sheet.row.inventory

07537.86882.45472.3
5162.8
3940.5
3287.4
2750.5
1670.7
1648.8
1604.6
1614.3
1273.4
1123.9
934.4
598
530.5
494.8
607.6
532
472.8
305.1
355.3
120.5
82.8
85
52.3
49.6
18
12.5

balance-sheet.row.other-current-assets

0704.8429.1885.4
733.4
599.5
296
315.3
72.1
95.5
11.2
4.2
4.3
1.9
14.3
475.2
-59.2
210.6
6.5
3.3
0.5
19
16.1
6
207.7
117
96.6
132.7
77
57.4

balance-sheet.row.total-current-assets

033792.635279.230424.6
25084.8
20403.4
18001.7
15056.5
10764.3
8325.4
8664
6986.5
8381.5
6049.1
5937.7
3306.9
2417.3
2517.1
2416.4
1961.9
1779.7
2103.4
1407.2
1044.9
671.4
430.5
510.1
216.7
106.7
103.4

balance-sheet.row.property-plant-equipment-net

022239.416028.113283.9
13002.7
11085.1
9123.1
8315.9
6304.7
5764.9
5681.4
4907.5
3479.7
2627.3
1695.7
1258.8
1145.3
1139.1
1274.4
1240.6
1054
777.2
570.5
349.4
260.6
175.5
74.4
41.6
4.4
3.3

balance-sheet.row.goodwill

01085210337.19400
8677.2
9014
8853.9
8464.3
3473.1
3303.4
3255
2976
1661.8
1585.1
296.4
51.1
51.1
51.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

017378.115925.313433.2
11498.6
10966.2
9192.1
8274.5
3650.6
3245.8
2911.9
2639.4
1782.3
1705.1
533.9
209
200.1
208.4
210.3
197.5
179
114.6
97.9
39.3
48
20.7
0.9
0.5
0
0

balance-sheet.row.goodwill-and-intangible-assets

028230.126262.422833.1
20175.9
19980.2
18046
16738.8
7123.7
6549.2
6166.9
5615.5
3444
3290.2
830.3
260.1
251.2
259.6
210.3
197.5
179
114.6
97.9
39.3
48
20.7
0.9
0.5
0
0

balance-sheet.row.long-term-investments

023123.824620.519679
21801.2
22564
23443.5
20904.5
18801.5
17200.5
14371.1
11560.7
9822.5
10011.5
7960.7
6652.3
3683.8
3465.1
2704.8
0
2108.4
1187.1
741.6
760.6
570.3
219.3
46.1
1.7
0
0

balance-sheet.row.tax-assets

0624.5442.6265.6
244.9
196.1
173.1
144.5
129.6
102.5
101.2
88.1
31.5
16.7
18.4
11.4
12.9
11.8
5.6
0
20.1
36.5
322.4
15.5
-555.5
-211.5
10.6
10.3
0
0

balance-sheet.row.other-non-current-assets

05459.34531.26807.4
3376.5
1890.9
1763.9
810.8
644
259.3
351.6
316.9
347.9
295.9
377.5
37.6
28.5
42.3
22.3
2268.7
29.4
0
0
-2.4
576.3
223.8
4.9
16.3
0.2
0

balance-sheet.row.total-non-current-assets

07967771884.762869.2
58601.2
55716.3
52549.6
46914.5
33003.5
29876.3
26672.3
22488.6
17125.6
16241.7
10882.5
8220.2
5121.6
4917.9
4217.5
3706.8
3390.8
2115.5
1732.4
1162.4
899.7
427.8
137
70.4
4.6
3.3

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0113469.6107163.993293.8
83686
76119.6
70551.4
61971
43767.8
38201.7
35336.3
29475.2
25507.1
22290.8
16820.1
11527.1
7538.9
7435
6633.9
5668.7
5170.5
4218.8
3139.6
2207.3
1571.1
858.2
647.1
287.1
111.3
106.7

balance-sheet.row.account-payables

06159.662845063.7
3289
2397.3
2333.3
1781.9
1149.4
1048.6
905
1136.4
903.7
939.9
827.3
491.3
398
357.8
530.9
560.3
484
339.3
326.3
89.5
70.5
63.6
36.9
50.8
10.8
5.7

balance-sheet.row.short-term-debt

019555.117402.914547.6
14911.8
8920.5
10536.8
10478.2
5650.4
7334.2
3950.7
1424.2
875.3
2187.1
1830.4
1583
502.5
1556.4
1465.2
786.3
682
466.3
772.3
627.5
129.7
39.6
0
22.5
29.5
21

balance-sheet.row.tax-payables

0537929.8727.5
564.7
759.6
478.9
480.1
478.2
503.8
342.9
288.9
162
111.7
247.4
48.9
49.5
73.7
42.1
27.8
38
62.6
61.3
9.5
16.2
8
12.1
10.4
0
-0.1

balance-sheet.row.long-term-debt-total

015554.512844.99697.4
9103
12987.1
12670.1
9814.9
5571
3571.5
3856.7
4199.7
4280.2
3915.1
2758.3
1284.5
1180.5
746.8
545.1
981.2
752.8
1026.9
45.8
25.2
25.2
13.8
30.1
0.5
0.4
14.3

Deferred Revenue Non Current

0639.4632.4512.8
482.2
417.3
363.5
397.1
346.7
169.3
139.6
404.5
627.6
374.2
57.8
64.9
65.2
70.1
-449
-877.5
5.1
5.9
-38.8
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0125.29611.21528.6
54.6
249
4574.3
604.6
944.9
352.8
1337.1
309.5
729.9
221.9
110.6
67.6
541.3
44.1
18.8
40.1
33.6
34.1
32
27
16.4
9.2
37.3
0.6
22.7
34.1

balance-sheet.row.total-non-current-liabilities

023095.819756.915608.3
12829.4
19481.7
19035.4
15629.1
8408.9
6592.9
6696
6532.6
6309.3
5928.3
3723.4
2076.8
1337.8
900.5
642.4
1087.7
762.7
1035.3
53.9
25.2
27.9
13.8
42.1
0.5
0.4
14.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

02049.6745648.4
627.3
410.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

056853.35305544918.2
37701.7
36915.4
36958.6
32229.6
18517.5
17532.1
16233.3
11810.7
10202.5
10920
7426.9
4575.1
3093
3118.6
2985.3
2793.7
2356.7
2201.9
1466.2
884.7
352.6
201.1
116.4
154.5
79.3
81.1

balance-sheet.row.preferred-stock

01300.11198.41265.8
933.6
468
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

02672.42672.22562.9
2562.9
2562.9
2563.1
2495.1
2414.5
2314.1
2311.6
2240.5
2240.5
1904.4
1904.4
1237.8
1237.8
1237.8
952.1
832
826.5
381.9
381.9
293.8
293.8
226.1
150.7
58.8
20
20

balance-sheet.row.retained-earnings

024542.523216.921039.6
17505
15125.7
12771.5
11111.6
8993.8
6937
5457
7112.7
5703
4483.5
3717.7
3258.2
1184.8
715.1
262.9
349.3
411.3
372.5
182.1
143.4
108.6
114.4
46.8
27.5
6.2
2.9

balance-sheet.row.accumulated-other-comprehensive-income-loss

0-1300.1-1198.4-1265.8
-933.6
-468
-4436.3
-4000.5
-3047.9
-2592.5
-2164.5
-1671.5
-1213.5
-1061.4
-871.5
-654.1
-544.9
-478
0
-9
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

018469.918693.415589.5
16927.7
14199.5
17079.5
15720.6
13829.8
11523
11070.7
7650.6
6828.8
4445.4
3672.4
2634.7
2131.2
2397.4
1875.2
1218.6
1066.4
945.8
845.5
826.8
743.2
264.1
321.7
14.4
5.7
2.7

balance-sheet.row.total-stockholders-equity

045684.844582.539191.9
36995.5
31888.1
27977.7
25326.9
22190.2
18181.6
16674.8
15332.2
13558.8
9771.9
8423
6476.5
4008.9
3872.3
3090.2
2390.9
2304.1
1700.2
1409.5
1264
1145.5
604.5
519.1
100.7
32
25.6

balance-sheet.row.total-liabilities-and-stockholders-equity

0113469.6107163.993293.8
83686
76119.6
70551.4
61971
43767.8
38201.7
35336.3
29475.2
25507.1
22290.8
16820.1
11527.1
7538.9
7435
6633.9
5668.7
5170.5
4218.8
3139.6
2207.3
1571.1
858.2
647.1
287.1
111.3
106.7

balance-sheet.row.minority-interest

010931.59526.59183.6
8988.7
7316.1
5615
4414.6
3060.1
2488.1
2428.2
2332.3
1745.9
1599
970.2
475.5
437.1
444.1
558.3
484.2
509.7
316.7
263.9
58.7
73
52.6
11.6
32
0
0

balance-sheet.row.total-equity

056616.354108.948375.6
45984.3
39204.2
33592.7
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

025012.325549.123920.1
23771.3
23020.6
24059.6
21123.8
18850
17234.2
14404.9
11604.9
10047.3
10242.8
8179.4
6664
3683.9
3471
2706.9
2227.2
2113.6
1187.3
1026.9
760.6
570.3
219.3
46.1
1.7
0
0

balance-sheet.row.total-debt

035109.630247.724245
24014.8
21907.6
23206.9
20293.1
11221.3
10905.7
7807.4
5623.9
5155.5
6102.1
4588.7
2867.5
1683
2303.2
2010.3
1767.5
1434.8
1493.2
818.1
652.6
154.9
39.6
30.1
22.5
29.5
35.4

balance-sheet.row.net-debt

02141614006.413936.9
14053
12374.4
14660.4
13044.2
5225.3
6877.1
4111.7
2556.5
183
3207.6
1245.2
1570.8
677.3
1229.4
1021.1
1014.6
752
250.8
474
280.4
-188.5
-130.4
-299.7
-2.8
22.9
28.2

Pinigų srautų ataskaita

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. finansiniame kraštovaizdyje per pastarąjį laikotarpį pastebimas pastebimas laisvųjų pinigų srauto pokytis, rodantis NaN pokytį. Bendrovė neseniai išplėtė savo akcinį kapitalą išleisdama NaN, o tai rodo NaN skirtumą, palyginti su praėjusiais metais. Bendrovės investicinė veikla lėmė grynųjų pinigų panaudojimą, kuris ataskaitine valiuta sudarė NaN. Tai NaN pokytis, palyginti su praėjusiais metais. Tuo pačiu laikotarpiu bendrovė užregistravo NaN, NaN ir NaN, kurie yra svarbūs norint suprasti įmonės investavimo ir grąžinimo strategijas. Bendrovės finansinė veikla lėmė grynųjų pinigų panaudojimą NaN, o per metus skirtumas buvo NaN. Be to, bendrovė skyrė NaN dividendams akcininkams išmokėti. Kartu ji ėmėsi kitų finansinių manevrų, vadinamų NaN, kurie taip pat turėjo didelės įtakos jos pinigų srautams šiuo laikotarpiu. Šie komponentai kartu sudaro išsamų įmonės finansinės būklės ir strateginio požiūrio į pinigų srautų valdymą vaizdą.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

02895.13947.54987.4
3940
3743.5
3019.9
3585.3
3221.3
2870.7
2369.8
2399.9
1839.3
1384.8
1000.3
2564.3
760.9
690.2
292.8
237.9
282.1
298.2
161.7
141.1
135.8
94.4
64.9

cash-flows.row.depreciation-and-amortization

02965.22335.91834.4
1666.2
1472.1
1320.1
938.6
732.9
649.3
558.4
415.5
286.2
209.9
152.7
134.7
132.5
136.5
132.1
116.7
91.1
56.1
37.6
28.6
28.1
20.1
9.3

cash-flows.row.deferred-income-tax

0-2723.50-4038.6
-2605.1
-2733
-1876.1
-2322.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

035.954.564.3
55.2
109.1
72.3
10.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0-1081.2-1387.9259.7
-1401.4
-494.6
-535.1
-212.7
-288.1
-101.8
-555.3
-44.5
-28.2
-88.6
11
599.1
13.6
-133.7
-5.4
-107
789.2
23.2
-35
-45.2
0.8
-78
-10.8

cash-flows.row.account-receivables

01605.1-2076.6-1795
-1559.9
-863.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-333.9-1430.1-464.7
-1253.4
-505.2
-564.7
-491.1
-65.4
-88.3
-105
-149.6
-155.1
-99.8
-66.2
-70.1
-27.6
109.6
-42.7
-67
-27
56
-11.2
-37.5
12.4
-14.4
-4.9

cash-flows.row.account-payables

0-1605.12076.61795
1559.9
863.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-2352.442.2724.5
-148
10.6
29.6
278.4
-222.7
-13.4
-450.3
105.1
126.9
11.2
77.2
669.2
41.2
-243.3
37.2
-40
816.2
-32.8
-23.8
-7.7
-11.6
-63.6
-5.9

cash-flows.row.other-non-cash-items

01322.7-732.4841.5
924.9
1125.3
949
580.8
-1556.1
-1797.2
-1172.7
-1759.4
-1431.8
-1189.5
-960.6
-3036.2
-673.9
-561.5
-234.6
-59.3
-957.3
-227.3
-61.8
-56.3
-26.3
1.7
3.2

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-5336.7-5888.8-4972.6
-4437.1
-3962.1
-3174.9
-2170.6
-1922
-1235.5
-1119.4
-1040.1
-1160.6
-796.8
-339.2
-348.1
-210.6
-209.7
-266.6
-222.6
-205
-264.1
-139.5
-141.5
-126.6
-78
-52.2

cash-flows.row.acquisitions-net

0-923.7-487.6381.4
-140.3
-818.8
-622.6
-7822.6
-249.4
109.9
-1145.7
-2225.2
30.8
12.7
2.1
-2.6
22.8
9.3
18.2
279.9
11.6
25.5
4.9
10.8
17.6
1
0

cash-flows.row.purchases-of-investments

0-943-1501.3-1424.6
-1070.1
-517.9
-2133.4
-2525.7
-1395.7
-2955.3
-1943.2
-364.1
-759.1
-1500.3
-1190.2
-770.2
-563.2
-543.7
-399.3
-349
-665.1
-134.9
-475.3
-317.8
-345.5
-253.5
-46

cash-flows.row.sales-maturities-of-investments

02809.34649.52168.3
2037.2
4916.2
1243.4
1550.6
1492.6
2127
1515.9
1540.7
1484.7
615.5
1348
755.5
822.8
632.3
329.6
76.6
45.4
535.7
254.8
243.5
30.2
43.4
0.4

cash-flows.row.other-investing-activites

0574.8-835.9-9.5
-1095.8
210.6
-557.4
464.2
-372.6
83.9
214.2
285.2
-574.4
-97.6
-85
-32.5
-15.6
58
-17
-222.6
33.9
-0.2
204.6
-282
-19.3
48.2
-2

cash-flows.row.net-cash-used-for-investing-activites

0-3819.3-4064-3857
-4706.2
-172
-5244.9
-10504.1
-2447.1
-1869.9
-2478.3
-1803.5
-978.6
-1766.5
-264.3
-397.8
56.1
-53.7
-335.1
-437.7
-779.2
162.1
-150.5
-487.1
-443.6
-238.9
-99.8

cash-flows.row.debt-repayment

0-21146.2-26280.1-27391.9
-15707.8
-13942.1
-9995.1
-9085.3
-9956.1
-7239.7
-2559.5
-2417.6
-3795.9
-4042.2
-2081.7
-1071.9
-1410.2
-1753.9
-1221
-817.9
-727.4
-665.6
-1613.8
-716.1
-311.2
-62.8
-52.4

cash-flows.row.common-stock-issued

0000
0
0
4851.4
3017.6
2728.5
116.1
1466.1
30.5
3151.1
0
637.8
18.9
16.1
17.2
0
0
9
951.5
8.4
6.7
437.6
0
372.4

cash-flows.row.common-stock-repurchased

0000
0
0
0
14821.2
7694.5
8990.2
4017.4
2105.1
-17.8
0
3083.4
1703.6
1286
2100.3
0
0
873.7
-589.4
1691
1200.8
-48.5
0
-342.4

cash-flows.row.dividends-paid

0-2455.2-2374.4-1914
-1834.6
-1864.4
-1775.5
-1433.5
-1193.5
-1109.3
-962.7
-804.5
-500.9
-437.3
-297.4
-268.6
-257.9
-237.6
-371.9
-200
-149.2
-94.9
-89.8
-78.2
-14.1
-13.4
-9.7

cash-flows.row.other-financing-activites

022265.13308328474.6
19009.5
13870.5
10056.8
2588.7
2172.7
-206.6
-98.3
154.3
3231.9
5392.5
480.3
18.9
16.1
17.2
1963.6
1165.7
8.5
984.4
24.1
41
402.5
117.1
369.8

cash-flows.row.net-cash-used-provided-by-financing-activities

0-1336.24428.5-831.3
1467.1
-1936
3137.5
9908.6
1446
550.7
1863.1
-932.1
2068.4
913
1822.5
401
-349.9
143.1
370.7
147.8
14.6
586.1
19.9
454.2
466.3
41
337.7

cash-flows.row.effect-of-forex-changes-on-cash

073.6128.3-134.7
-300.2
-5.1
-18
-172.5
80.5
36.6
8.9
-31.4
-12
-6
-3.8
-0.7
-4.6
-4.8
-1.2
-0.4
0
-0.1
0
0
0.1
0
0

cash-flows.row.net-change-in-cash

0-1667.74710.3-874.2
-959.5
1109.4
824.7
1812.3
1189.4
338.4
593.9
-1755.3
1743.4
-542.9
1757.7
264.3
-65.4
216.1
219.3
-102
-559.5
898.3
-28.2
35.3
161.2
-159.7
304.5

cash-flows.row.cash-at-end-of-period

09502.411170.16450.7
7324.9
8284.4
7175
6350.3
4538
3348.6
3010.2
2416.3
4171.6
2428.2
2971.1
1213.4
949.1
1014.4
800.2
580.9
682.9
1242.4
344.1
372.3
343.4
170
329.8

cash-flows.row.cash-at-beginning-of-period

011170.16459.77324.9
8284.4
7175
6350.3
4538
3348.6
3010.2
2416.3
4171.6
2428.2
2971.1
1213.4
949.1
1014.4
798.4
580.9
682.9
1242.4
344.1
372.3
337
182.2
329.8
25.3

cash-flows.row.operating-cash-flow

03414.24217.63948.7
2579.8
3222.4
2950.1
2580.2
2110
1621
1200.2
1011.6
665.5
316.6
203.4
261.9
233
131.5
184.9
188.3
205.1
150.1
102.5
68.2
138.4
38.2
66.6

cash-flows.row.capital-expenditure

0-5336.7-5888.8-4972.6
-4437.1
-3962.1
-3174.9
-2170.6
-1922
-1235.5
-1119.4
-1040.1
-1160.6
-796.8
-339.2
-348.1
-210.6
-209.7
-266.6
-222.6
-205
-264.1
-139.5
-141.5
-126.6
-78
-52.2

cash-flows.row.free-cash-flow

0-1922.5-1671.3-1023.8
-1857.3
-739.6
-224.8
409.6
188.1
385.5
80.8
-28.4
-495.1
-480.2
-135.8
-86.2
22.4
-78.2
-81.7
-34.3
0.1
-113.9
-37
-73.4
11.8
-39.8
14.3

Pajamų ataskaitos eilutė

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. pajamos, palyginti su ankstesniu laikotarpiu, pasikeitė NaN%. Pranešama, kad bendrasis 2196.HK pelnas yra NaN. Bendrovės veiklos sąnaudos yra NaN, palyginti su praėjusiais metais, jos pakito NaN%. Nusidėvėjimo ir amortizacijos sąnaudos yra NaN, o tai yra NaN% pokytis nuo praėjusio ataskaitinio laikotarpio. Pranešama, kad veiklos išlaidos yra NaN, kurios rodo NaN% pokytį per metus. Pardavimo ir rinkodaros išlaidos yra NaN, kuris yra NaN% рokytis, palyginti su praėjusiais metais. Naujausiais duomenimis pagrįsta EBITDA yra NaN, o tai reiškia NaN% augimą per metus. Veiklos pajamos yra NaN, kurios rodo NaN% pokytį, palyginti su praėjusiais metais. Grynųjų pajamų pokytis yra NaN%. Praėjusių metų grynosios pajamos buvo NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

income-statement-row.row.total-revenue

041399.543951.539005.1
30307
28585.2
24918.3
18533.6
14628.8
12608.6
12025.5
9996.4
7340.8
6485.5
4555.4
3872.3
3773.2
3693.3
3102
2988.5
2425.4
2154.6
1031.7
727.8
579.5
442.5
340.4
190.3
92.7
64.7

income-statement-row.row.cost-of-revenue

021595.323169.720228.3
13431.2
11543.4
10365.3
7609
6718.4
6308
6718.6
5543.4
4126.8
3991.1
2984.6
2610.7
2711.9
2693.8
2282.2
2076
1651.9
1564
668.1
448.9
307.6
248.4
209.3
116.5
65.3
50.1

income-statement-row.row.gross-profit

019804.220781.918776.8
16875.8
17041.7
14553
10924.6
7910.5
6300.6
5307
4453
3214
2494.4
1570.9
1261.6
1061.4
999.5
819.8
912.5
773.6
590.5
363.6
279
271.9
194
131.1
73.9
27.3
14.5

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0-17.92683.72276.4
1841.5
1666
44.1
-13.2
181.9
78.3
324.6
97.9
89.9
158.8
62.1
56
30.9
21.9
60.5
96.5
52.8
42.7
18.1
12.3
18.9
10.9
8
10
-0.3
0.5

income-statement-row.row.operating-expenses

018240.91714516055.8
14045.6
14425.7
12185.7
8621
6168.5
4827.1
4114.5
3339.1
2620.4
2149
1394.5
1098.2
939.7
834.5
794.6
829.5
658.2
549.4
304.1
206.9
172.3
102.3
62.6
31.6
14.3
4.9

income-statement-row.row.cost-and-expenses

039836.240314.736284.1
27476.8
25969.1
22551
16230
12886.8
11135.2
10833.1
8882.5
6747.2
6140.2
4379.1
3708.8
3651.6
3528.3
3076.7
2905.5
2310.1
2113.4
972.2
655.7
480
350.7
271.9
148.1
79.6
55

income-statement-row.row.interest-income

0363.6282.6233.7
199.6
186.6
145.7
79.2
80.9
56.2
69.8
63.8
29.7
51.6
19.6
14.5
17.9
12.5
13.8
17.5
13.7
8.7
2.9
13.7
8.1
0
0
0
0
0

income-statement-row.row.interest-expense

01324.8963.8822.5
881
1074.7
929.7
577.5
488.2
470
415
350.5
370.6
314
162.4
132.4
149.6
130.6
83.3
72
37
45.9
36.2
23.7
9.8
-6.1
-3.3
3.1
3
1.5

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-42.9-3722.2-259.9
-43.3
-1887.5
1212.3
1758.1
1829.5
1898.4
1525.6
1792.3
1529.5
1381.3
1025.6
3101.2
714
591.4
249.1
124.7
159.4
282.5
104.1
76.8
42.6
12.8
5.2
-3.1
-3.1
-1.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0-17.92683.72276.4
1841.5
1666
44.1
-13.2
181.9
78.3
324.6
97.9
89.9
158.8
62.1
56
30.9
21.9
60.5
96.5
52.8
42.7
18.1
12.3
18.9
10.9
8
10
-0.3
0.5

income-statement-row.row.total-operating-expenses

0-42.9-3722.2-259.9
-43.3
-1887.5
1212.3
1758.1
1829.5
1898.4
1525.6
1792.3
1529.5
1381.3
1025.6
3101.2
714
591.4
249.1
124.7
159.4
282.5
104.1
76.8
42.6
12.8
5.2
-3.1
-3.1
-1.4

income-statement-row.row.interest-expense

01324.8963.8822.5
881
1074.7
929.7
577.5
488.2
470
415
350.5
370.6
314
162.4
132.4
149.6
130.6
83.3
72
37
45.9
36.2
23.7
9.8
-6.1
-3.3
3.1
3
1.5

income-statement-row.row.depreciation-and-amortization

02965.22335.92986.4
2171.8
1472.1
1320.1
938.6
732.9
649.3
558.4
415.5
286.2
209.9
152.7
134.7
132.5
136.5
132.1
116.7
91.1
56.1
37.6
28.6
28.1
20.1
9.3
-7
3.3
1

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

03307.58296.66313.7
4721.1
6413.2
3535.5
4074.9
3399.4
3297.2
2394.3
2818.8
2036
1580.5
1140.5
3212
807.6
736.7
347.1
234.5
298.2
329.4
168.5
144.1
141.9
106.3
77.3
49.3
9.8
8.7

income-statement-row.row.income-before-tax

03264.64574.46053.8
4677.8
4525.8
3579.6
4061.7
3571.5
3371.8
2718.1
2906.3
2123
1726.7
1202
3264.7
835.7
756.4
341
269.3
312.9
347.8
175.1
152.7
151.4
110.9
79.5
49.3
9.7
8.7

income-statement-row.row.income-tax-expense

0369.5626.91066.4
737.9
782.2
559.7
476.5
350.2
501.2
348.2
506.3
283.8
341.8
201.6
700.4
74.7
66.2
48.2
31.4
30.8
49.6
13.6
11.6
15.7
16.5
12.9
9.1
3.4
2.7

income-statement-row.row.net-income

02386.33730.84728.7
3662.8
3321.6
2707.9
3124.5
2805.8
2460.1
2112.9
2027.1
1563.9
1165.6
863.7
2498.2
690.9
625.8
259.2
159
215.3
263.6
147.2
135.5
128.5
92.2
63.7
36
6.4
6
Panašios akcijos
Jus taip pat gali dominti:
CHSYF
China Medical System Holdings Limited.
0.9313 USD
PNK
600479.SS
ZhuZhou QianJin Pharmaceutical Co.,Ltd.
10.92 CNY
SHH
WOCKPHARMA.BO
Wockhardt Limited.
532.5 INR
BSE
185750.KS
Chong Kun Dang Pharmaceutical Corp..
100300 KRW
KSC
ERIS.NS
Eris Lifesciences Limited.
848.1 INR
NSE
300601.SZ
Shenzhen Kangtai Biological Products Co., Ltd..
22.39 CNY
SHZ
TKPHF
Takeda Pharmaceutical Company Limited.
26.83 USD
PNK
MVP.AX
Medical Developments International Limited.
0.61 AUD
ASX
APLLTD.NS
Alembic Pharmaceuticals Limited.
1001.35 INR
NSE
128940.KS
Hanmi Pharm. Co., Ltd..
321500 KRW
KSC
002390.KS
HANDOK Inc..
13700 KRW
KSC

Dažnai užduodami klausimai

Kas yra Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) bendras turtas?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) bendras turtas yra 113469604813.000.

Kokios yra įmonės metinės pajamos?

Metinės pajamos yra N/A.

Kokia yra įmonės pelno marža?

Įmonės pelno marža yra 0.475.

Koks yra įmonės laisvųjų pinigų srautas?

Laisvųjų pinigų srautas yra -0.539.

Kokia yra įmonės grynojo pelno marža?

Grynojo pelno marža yra 0.049.

Kokios yra bendros įmonės pajamos?

Bendrosios pajamos yra 0.071.

Kas yra Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) grynasis pelnas (grynosios pajamos)?

Grynasis pelnas (grynosios pajamos) yra 2386265813.000.

Kokia yra bendra įmonės skola?

Bendra skola yra 35109563838.000.

Koks yra veiklos sąnaudų skaičius?

Veiklos sąnaudos yra 18240906770.000.

Koks yra įmonės grynųjų pinigų skaičius?

Įmonės grynieji pinigai yra 0.000.